T. Wolska-Smoleń

Thalidomide treatment of resistant or relapsed multiple myeloma patients.

A. Dmoszyńska, A. Skotnicki, A. Hellmann, 2001, Haematologica.

[Multiple myeloma: the role of angiogenesis and therapeutic application of thalidomide].

A. Skotnicki, A. Jurczyszyn, T. Wolska-Smoleń, 2003, Przeglad lekarski.

ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis.

Martin C. Müller, A. Skotnicki, A. Hochhaus, 2003, Leukemia research.

An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma

K. Sułek, T. Robak, A. Dmoszyńska, 2004, British Journal of Cancer.

The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma--a report by the Polish Myeloma Study Group.

W. Jędrzejczak, A. Dmoszyńska, A. Skotnicki, 2010, Leukemia research.

The use of the Congo red-related dye DBACR to recognize the heavy chain-derived abnormality of myeloma immunoglobulins

Leszek Konieczny, Irena Roterman, Barbara Stopa, 2006, Archivum Immunologiae et Therapiae Experimentalis.